Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Telix Pharmaceuticals (Innovations) Pty Limited
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
The New York Proton Center
Novelwise Pharmaceutical Corporation
Iambic Therapeutics, Inc
NaviFUS Corporation
Waikato Hospital
Parabilis Medicines, Inc.
NaviFUS Corporation
NaviFUS Corporation
Stemline Therapeutics, Inc.
Actuate Therapeutics Inc.
University Hospital, Caen
Ottawa Hospital Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Avera McKennan Hospital & University Health Center
Pfizer
Tianjin Medical University Cancer Institute and Hospital
Vanderbilt-Ingram Cancer Center
Eli Lilly and Company
University of Colorado, Denver
National Institutes of Health Clinical Center (CC)
Rigel Pharmaceuticals
RasCal Therapeutics, Inc.
Coherence Neuro Australia Pty Limited
Children's Hospital of Philadelphia
Beijing Tiantan Hospital
Baptist Health South Florida
UMC Utrecht
The Children's Hospital of Zhejiang University School of Medicine
Baptist Health South Florida
GT Medical Technologies, Inc.
Emory University
Children's Oncology Group
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
Memorial Sloan Kettering Cancer Center
Essen Biotech
Essen Biotech
Pediatric Brain Tumor Consortium
St. Jude Children's Research Hospital
Medical University of South Carolina
Uppsala University